Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antitretroviral therapy [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 546-548

  Verucchi, Gabriella ^a   Calza, Leonardo ^a   Manfredi, Roberto ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CORTICOSTEROID; DIDANOSINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CYTOLYSIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037961074     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00019     Document Type: Letter

References (14)

1. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:75-80.
2. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002; 35:182-188.
3. Savès M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations, Aquitaine cohort, France, 1996-1998. AIDS. 1999;17:F115-F121.
4. Gisolf EH, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 2000;31:1234-1239.
5. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:316-318.
6. Martin-Carbonero L, Nunez M, Rios P, et al. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus coinfected patients is not related to immune reconstitution. AIDS. 2002;16:1423-1425.
7. Shintaku M, Nasu K, Shimizu T. Fulminant hepatic failure in an AIDS patient: possible zidovudine-induced hepatotoxicity. Am J Gastroenterol. 1993;88:464-466.
8. Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol. 1995;90:1433-1436.
9. ter Hofstede HJ, de Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11:611-616.
10. Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000;30:198-200.
11. Olano JP, Borucki MJ, Wen JW, et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis. 1995;21:973-976.
12. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
13. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity: a challenge for the hepatologists? J Hepatol. 2002;36:283-294.
14. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe liver toxicity following the introduction of HAART. J Acquir Immune Defic Syndr. 2001;27:426-431.